Entera Bio Ltd., a Jerusalem-based clinical-stage biopharmaceutical company, is making strides in the development and commercialization of orally delivered large molecule therapeutics for unmet medical needs. The company boasts a portfolio of lead product candidates, including EB612, currently in Phase II clinical trials to treat hypoparathyroidism, and EB613, which has completed Phase II clinical trials for osteoporosis treatment and is in Phase I clinical trials for non-union fractures. Entera Bio also has a highly valuable research collaboration and license agreement with Amgen Inc. to develop and discover clinical candidates for inflammatory disease and other serious illnesses. Incorporated in 2009, Entera Bio Ltd.'s advancements in the biopharmaceutical industry are poised to make significant contributions in the near future.
Entera Bio Ltd.'s ticker is ENTX
The company's shares trade on the NASDAQ stock exchange
They are based in Jerusalem, Israel
There are 11-50 employees working at Entera Bio Ltd.
It is https://www.enterabio.com/
Entera Bio Ltd. is in the Healthcare sector
Entera Bio Ltd. is in the Biotechnology industry
The following five companies are Entera Bio Ltd.'s industry peers: